Chongqing Huiyuan Pharma Acquires Singapore Chinese Medicines And Health
This article was originally published in PharmAsia News
Chongqing Huiyuan Pharma has recently completed the acquisition of Singapore's second-largest pharmaceutical retail chain company - Singapore Chinese Medicines and Health - with RMB 10 million ($1.46 million). Huiyuan will set up a large-scale one-stop TCM supermarket in Singapore that integrates diagnosis services by TCM physicians and sale of health products and Chinese herbal slices. The firm will also establish branches in Southeast Asia to develop TCM clinics, training, exhibition and wholesale businesses. The acquisition is set to boost sales of Chongqing-made Chinese crude medicines and herbal slices in the Singapore market, as well as enhance Chongqing city's TCM product expansion in Southeast Asia. (Click here for more - Chinese Language)
You may also be interested in...
AstraZeneca's research head admits that half dose approach was a lucky mistake - but one that could boost the vaccine's effectiveness and supplies. The US regulator may not be persuaded, however.
HBW Insight speaks to new Global Self-Care Federation chair and Bayer CH chief Heiko Schipper about the role that self-care can play in alleviating pressure on national health care systems, the importance of self-care's scientific credentials and of maintaining supply chain continuity during the coronavirus pandemic.
Increasingly looking to China to commercialize their latest therapies, multinationals may be leaping into unknown waters to navigate an intellectual property judiciary and administrative maze, in a country where some copy drugs have been approved before patent expiry. With a government trying to balance innovation and access, two recent rulings involving AstraZeneca shed rare light onto China’s protections for innovation, with advisors pointing to challenges and success factors.